Eli Lilly & Biogen's Alzheimer's drugs may offer minimal impact despite aggressive marketing. Click here to get insights on ...

Ever since Biogen and Eisai’s Aduhelm (aducanemab) was approved in 2021 as the first antibody to treat Alzheimer’s disease by ...

New evidence of effectiveness is cause to drop a Biden restriction on Medicare coverage for anti-amyloid treatments.

A Japanese health ministry panel on Wednesday approved a plan to cut the price of Lecanemab, an Alzheimer's drug codeveloped by Japanese drugmaker Eisai Co. and US industry peer Biogen Inc., by 15 ...

Loved ones, caregivers and supporters of Coloradans living with Alzheimer’s disease will join together Saturday, Aug. 23, for ...

Why does the brain of some people stay sharp into their 80s and beyond? An expert explains what 25 years of exploring the ...

The progressive supranuclear palsy market is expected to witness steady growth due to increasing disease awareness, advancements in diagnosti ...